Document Basket

Saved pages

Saved documents

Please note: This information is saved in a cookie. In case your browser deletes cookies after a session, the information will be lost.


DKSH provides easy access to Sato’s products in China

DKSH, the leading Market Expansion Services provider with a focus on Asia, has been appointed by Sato Pharmaceutical, a well-known pharmaceutical company from Japan, to drive growth for the company’s Hakubi and Tsuruko brands in China.

Media release

DKSH provides easy access to Sato’s products in China

DKSH, the leading Market Expansion Services provider with a focus on Asia, has been appointed by Sato Pharmaceutical, a well-known pharmaceutical company from Japan, to drive growth for the company’s Hakubi and Tsuruko brands in China.

Shanghai, China, September 26, 2017 – DKSH Business Unit Healthcare, a leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, and Sato Pharmaceutical have signed a strategic cooperation agreement for the Chinese market. A ceremony was conducted to mark the occasion, attended by senior executives from both parties.

 

Under the agreement, DKSH has been entrusted to provide marketing and sales, distribution and logistics services for its Hakubi, a fruit-flavor collagen drink, and Tsuruko, a non-stimulating skin care cream. Consumers in China will have access to the products across personal care stores, mom and baby stores, as well as through online channels. The collaboration is an extension of the partnerships with Sato Pharmaceutical and DKSH in Hong Kong, Malaysia and Taiwan.

 

“The goal of our company is to help people to lead healthier, happier lives. We are delighted to collaborate with DKSH, a trusted healthcare partner that has a deep understanding of the market and extensive market presence in the healthcare industry. With the help of DKSH, we continue to drive the development of our advanced, highly value-added products, and most importantly, our products are easily accessible to end-consumers,” said Seiichi Sato, President and CEO of Sato Pharmaceutical.

 

Teresa Chen, Regional Vice President, Healthcare, DKSH Greater China and Korea, added: “To work with Sato Pharmaceutical in China means we are building further strength for our local operation. We believe our professional market and sales performance with its wide coverage of retail and online channels will accomplish further promotion and popularization of the Sato pharmaceutical brand in China. We are proud to support Sato Pharmaceutical with its China expansion while helping more people in the country to get access to high-quality products.”